Literature DB >> 12085970

Prostate carcinoma skeletal metastases: cross-talk between tumor and bone.

E T Keller1, J Zhang, C R Cooper, P C Smith, L K McCauley, K J Pienta, R S Taichman.   

Abstract

The majority of men with progressive prostate cancer develop metastases with the skeleton being the most prevalent metastatic site. Unlike many other tumors that metastasize to bone and form osteolytic lesions, prostate carcinomas form osteoblastic lesions. However, histological evaluation of these lesions reveals the presence of underlying osteoclastic activity. These lesions are painful, resulting in diminished quality of life of the patient. There is emerging evidence that prostate carcinomas establish and thrive in the skeleton due to cross-talk between the bone microenvironment and tumor cells. Bone provides chemotactic factors, adhesion factors, and growth factors that allow the prostate carcinoma cells to target and proliferate in the skeleton. The prostate carcinoma cells reciprocate through production of osteoblastic and osteolytic factors that modulate bone remodeling. The prostate carcinoma-induced osteolysis promotes release of the many growth factors within the bone extracellular matrix thus further enhancing the progression of the metastases. This review focuses on the interaction between the bone and the prostate carcinoma cells that allow for development and progression of prostate carcinoma skeletal metastases.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 12085970     DOI: 10.1023/a:1015599831232

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  56 in total

Review 1.  Targeting chemokine (C-C motif) ligand 2 (CCL2) as an example of translation of cancer molecular biology to the clinic.

Authors:  Jian Zhang; Lalit Patel; Kenneth J Pienta
Journal:  Prog Mol Biol Transl Sci       Date:  2010       Impact factor: 3.622

2.  MRI for the detection of prostate cancer origin vertebral metastases in the preosteoblastic phase.

Authors:  Swaroop Revannasiddaiah; Madhup Rastogi; Pragyat Thakur; Manoj Kumar Gupta; Ashwani Sood; Chittranjan Sharma
Journal:  BMJ Case Rep       Date:  2012-07-09

3.  Lack of noggin expression by cancer cells is a determinant of the osteoblast response in bone metastases.

Authors:  Ruth Schwaninger; Cyrill A Rentsch; Antoinette Wetterwald; Geertje van der Horst; Rutger L van Bezooijen; Gabri van der Pluijm; Clemens W G M Löwik; Karin Ackermann; Walter Pyerin; Freddie C Hamdy; George N Thalmann; Marco G Cecchini
Journal:  Am J Pathol       Date:  2007-01       Impact factor: 4.307

4.  p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1.

Authors:  Christopher L Hall; Honglai Zhang; Shobun Baile; Mats Ljungman; Stuart Kuhstoss; Evan T Keller
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

5.  Phase I pharmacokinetic and biodistribution study with escalating doses of ²²³Ra-dichloride in men with castration-resistant metastatic prostate cancer.

Authors:  Jorge A Carrasquillo; Joseph A O'Donoghue; Neeta Pandit-Taskar; John L Humm; Dana E Rathkopf; Susan F Slovin; Matthew J Williamson; Kristine Lacuna; Anne-Kirsti Aksnes; Steven M Larson; Howard I Scher; Michael J Morris
Journal:  Eur J Nucl Med Mol Imaging       Date:  2013-05-08       Impact factor: 9.236

6.  Radiation safety considerations for the use of ²²³RaCl₂ DE in men with castration-resistant prostate cancer.

Authors:  Lawrence T Dauer; Matthew J Williamson; John Humm; Joseph O'Donoghue; Rashid Ghani; Robert Awadallah; Jorge Carrasquillo; Neeta Pandit-Taskar; Anne-Kirsti Aksnes; Colin Biggin; Vigdis Reinton; Michael Morris; Jean St Germain
Journal:  Health Phys       Date:  2014-04       Impact factor: 1.316

Review 7.  The prostate cancer bone marrow niche: more than just 'fertile soil'.

Authors:  Elisabeth A Pedersen; Yusuke Shiozawa; Kenneth J Pienta; Russell S Taichman
Journal:  Asian J Androl       Date:  2012-02-27       Impact factor: 3.285

8.  A destructive cascade mediated by CCL2 facilitates prostate cancer growth in bone.

Authors:  Xin Li; Robert Loberg; Jinhui Liao; Chi Ying; Linda A Snyder; Kenneth J Pienta; Laurie K McCauley
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

9.  Type I collagen receptor (alpha2beta1) signaling promotes prostate cancer invasion through RhoC GTPase.

Authors:  Christopher L Hall; Cara W Dubyk; Tracy A Riesenberger; Daniel Shein; Evan T Keller; Kenneth L van Golen
Journal:  Neoplasia       Date:  2008-08       Impact factor: 5.715

10.  Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis.

Authors:  Sanjeev K Baniwal; Omar Khalid; Yankel Gabet; Ruchir R Shah; Daniel J Purcell; Deepak Mav; Alice E Kohn-Gabet; Yunfan Shi; Gerhard A Coetzee; Baruch Frenkel
Journal:  Mol Cancer       Date:  2010-09-23       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.